Arcutis Biotherapeutics Inc (ARQT)vsVertex Pharmaceuticals Inc (VRTX)
ARQT
Arcutis Biotherapeutics Inc
$31.45
-0.73%
HEALTHCARE · Cap: $3.95B
VRTX
Vertex Pharmaceuticals Inc
$540.00
+1.95%
HEALTHCARE · Cap: $126.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 2613% more annual revenue ($12.59B vs $463.98M). VRTX leads profitability with a 35.0% profit margin vs 6.2%. VRTX trades at a lower P/E of 28.9x. VRTX earns a higher WallStSmart Score of 64/100 (C+).
ARQT
Hold45
out of 100
Grade: D
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+79.2%
Fair Value
$128.09
Current Price
$31.45
$96.64 discount
Margin of Safety
+45.0%
Fair Value
$952.30
Current Price
$540.00
$412.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 59.3% year-over-year
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Trading at 17.9x book value
0.0% earnings growth
6.2% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARQT
The strongest argument for ARQT centers on Revenue Growth. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ARQT
The primary concerns for ARQT are Price/Book, EPS Growth, Profit Margin. A P/E of 142.9x leaves little room for execution misses.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ARQT profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
ARQT carries more volatility with a beta of 1.58 — expect wider price swings.
ARQT is growing revenue faster at 59.3% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 45/100), backed by strong 35.0% margins and 12.5% revenue growth. ARQT offers better value entry with a 79.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arcutis Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?